Research and Markets: Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs.Business Editors DUBLIN, Ireland--(BUSINESS WIRE)--May 12, 2004 Research and Markets (http://www.researchandmarkets.com) has announced the addition of Urinary Incontinence Urinary Incontinence Definition Urinary incontinence is unintentional loss of urine that is sufficient enough in frequency and amount to cause physical and/or emotional distress in the person experiencing it. : Market Update - Growing Market Brings Opportunities for New Drugs to their offering. Introduction Urinary incontinence can be defined as 'the involuntary loss of urine which is objectively demonstrable and a social or hygienic problem'. Within this broad definition, urinary incontinence in adults can be further classified into four main types of incontinence based on the symptoms experienced at presentation and the physiological characteristics associated with the disease. These four main types of incontinence are: overflow incontinence overflow incontinence Paradoxic incontinence Dribbling of urine due to chronic overdistension of the bladder–volume from 1000 to 3000 mL, normal, ±500 ml, with attenuation of the muscle; this may be confused–and therefore is paradoxic–with , stress urinary incontinence stress urinary incontinence n. See stress incontinence. , urge incontinence urge incontinence n. Leakage of urine when the desire to void is strong. Also called urgency incontinence. urge incontinence and mixed incontinence. Partly in a bid to increase the number and type of patients with incontinence eligible for clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has adopted an alternative term, 'overactive bladder', to describe a syndrome that encompasses not only urge incontinence, but also urgency, frequency, dysuria dysuria /dys·uria/ (dis-u´re-ah) painful or difficult urination.dysu´ric dys·u·ri·a n. Difficult or painful urination. and nocturia. Detrol, Ditropan XL and Detrol LA are all approved in the US and Europe for the treatment of overactive bladder Overactive Bladder Definition Overactive bladder is the leakage of large amounts of urine at unexpected times, including during sleep. Description (OAB OAB Ordem dos Advogados do Brasil (Brazil) OAB Offline Address Book OAB Over-Active Bladder (urology) OAB Outlook Address Book (Microsoft) OAB Ocean Affairs Board ). Pfizer's aggressive marketing activity to support the launch of Detrol (tolterodine) also successfully raised wider disease awareness. With the two market leading drugs both suffering from poor side-effect profiles, and considerable scope for improved efficacy, there is still considerable unmet need in the market. Scope of this Report - Overview of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population - Review of the performance of the leading drugs in the market, Pfizer's Detrol (tolterodine) and ALZA's Ditropan XL (oxybutynin chloride ox·y·bu·ty·nin chloride n. An anticholinergic drug used to treat incontinence and other urinary symptoms. oxybutynin chloride (ok´sēbū´tinin klor´īd), ) - Analysis of the potential of Yamanouchi's Vesicare (solifenacin succinate), Novartis's Enablex (darifenacin) and Eli Lilly's duloxetine Report Highlights - Fighting off strong competition from Yamanouchi's Vesicare and Enablex from Novartis, Pfizer's Detrol will maintain its position as urinary incontinence market leader. - Of the two drugs expected to launch in 2004, Vesicare is expected to prove more popular than Enablex, backed up by favourable results from a head-to-head study with Detrol. Thanks in part to this; its sales will surge to $971m by 2011 while Enablex will reach $743m. - In the stress urinary incontinence sub-indication, Eli Lilly's duloxetine will enjoy considerable success as the market expands, with sales of $488m forecast for 2011. Reasons to Purchase - Gauge the potential of the key late-stage pipeline products - Understand the factors driving the urinary incontinence market - Evaluate the patient potential in each of the key urinary incontinence sub-indications For more information visit http://www.researchandmarkets.com/reports/c1955 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion